Deferred Cytoreductive Nephrectomy Following Presurgical Vascular Endothelial Growth Factor Receptor-targeted Therapy in Patients with Primary Metastatic Clear Cell Renal Cell Carcinoma: A Pooled Analysis of Prospective Trial Data (European Urology Oncology)

In intermediate-risk metastatic renal cell carcinoma patients, presurgical therapy with vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) followed by cytoreductive nephrectomy in the absence of progression yields favourable overall survival results when compared with upfront cytoreductive nephrectomy followed by VEGFR-TKI.